Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies

被引：1
|
作者：
Yifei, L. [1 ]
Skup, M. [2 ]
Yang, M. [3 ]
Qi, C. [3 ]
Doctor, T. [3 ]
机构：
[1] Univ Missouri, Sch Pharm, Kansas City, MO 64110 USA
[2] AbbVie, Chicago, IL USA
[3] Anal Grp, Boston, MA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.569
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P445
引用
收藏
页码：S334 / S334
页数：1
相关论文
共 50 条
  • [1] Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
    Yifei Liu
    Martha Skup
    Min Yang
    Cynthia Z. Qi
    Eric Q. Wu
    Advances in Therapy, 2022, 39 : 3711 - 3734
  • [2] Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
    Liu, Yifei
    Skup, Martha
    Yang, Min
    Qi, Cynthia Z.
    Wu, Eric Q.
    ADVANCES IN THERAPY, 2022, 39 (08) : 3711 - 3734
  • [3] Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
    Yifei Liu
    Martha Skup
    Min Yang
    Cynthia Z. Qi
    Eric Q. Wu
    Advances in Therapy, 2022, 39 : 5300 - 5300
  • [4] Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018 (vol 39, pg 3711, 2022)
    Liu, Yifei
    Skup, Martha
    Yang, Min
    Qi, Cynthia Z.
    Wu, Eric Q.
    ADVANCES IN THERAPY, 2022, 39 (11) : 5300 - 5300
  • [5] The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
    Hillhouse, Erin
    Mathurin, Karine
    Bibeau, Joelle
    Parison, Diana
    Rahal, Yasmine
    Lachaine, Jean
    Beauchemin, Catherine
    ADVANCES IN THERAPY, 2022, 39 (01) : 455 - 487
  • [6] The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
    Erin Hillhouse
    Karine Mathurin
    Joëlle Bibeau
    Diana Parison
    Yasmine Rahal
    Jean Lachaine
    Catherine Beauchemin
    Advances in Therapy, 2022, 39 : 455 - 487
  • [7] Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis
    Melville, Andrew R.
    Yusof, Md Yuzaiful Md
    Fitton, John
    Garcia-Montoya, Leticia
    Bailey, Lynda
    Dass, Shouvik
    Emery, Paul
    Buch, Maya H.
    Saleem, Benazir
    RHEUMATOLOGY, 2021, 60 (08) : 3679 - 3688
  • [8] ECONOMIC IMPACT OF AN ORIGINATOR-TO-BIOSIMILAR NON-MEDICAL SWITCH IN THE REAL-WORLD SETTING: A SYSTEMATIC LITERATURE REVIEW
    Hillhouse, E.
    Bibeau, J.
    Parison, D.
    Rahal, Y.
    Lachaine, J.
    Beauchemin, C.
    VALUE IN HEALTH, 2021, 24 : S15 - S16
  • [9] Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
    Numan, Syed
    Faccin, Freddy
    ADVANCES IN THERAPY, 2018, 35 (09) : 1295 - 1332
  • [10] Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
    Syed Numan
    Freddy Faccin
    Advances in Therapy, 2018, 35 : 1295 - 1332
12345